Co-delivery of doxorubicin and Bmi1 siRNA by folate receptor targeted liposomes exhibits enhanced anti-tumor effects in vitro and in vivo.
about
Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinomaMiR-375 and Doxorubicin Co-delivered by Liposomes for Combination Therapy of Hepatocellular Carcinoma.Nanocrystals of a new camptothecin derivative WCN-21 enhance its solubility and efficacyZwitterionic poly(carboxybetaine)-based cationic liposomes for effective delivery of small interfering RNA therapeutics without accelerated blood clearance phenomenon.Anti-tumor Efficiency of Lipid-coated Cisplatin Nanoparticles Co-loaded with MicroRNA-375Folate-modified Chitosan Nanoparticles Containing the IP-10 Gene Enhance Melanoma-specific Cytotoxic CD8(+)CD28(+) T Lymphocyte ResponsesCombination Therapy for Ulcerative Colitis: Orally Targeted Nanoparticles Prevent Mucosal Damage and Relieve Inflammation.Folate-targeted star-shaped cationic copolymer co-delivering docetaxel and MMP-9 siRNA for nasopharyngeal carcinoma therapy.MiR-101 and doxorubicin codelivered by liposomes suppressing malignant properties of hepatocellular carcinoma.Nanocarriers for delivery of siRNA and co-delivery of siRNA and other therapeutic agents.Oestrone-targeted liposomes for mitoxantrone delivery via oestrogen receptor - synthesis, physicochemical characterization and in-vitro evaluation.Endocytosis in gene therapy with non-viral vectors.Knockdown of Bmi1 inhibits bladder cancer cell growth both in vitro and in vivo by blocking cell cycle at G1 phase and inducing apoptosis.Liposome-targeted delivery for highly potent drugs.Engineering liposomal nanoparticles for targeted gene therapy.Combinatorial therapeutic approaches with RNAi and anticancer drugs using nanodrug delivery systems.Epidermal growth factor receptor-targeted sonoporation with microbubbles enhances therapeutic efficacy in a squamous cell carcinoma model.EphA2 Targeted Doxorubicin-Nanoliposomes for Osteosarcoma Treatment.Recent advances in co-delivery systems based on polymeric nanoparticle for cancer treatment.Targeted co-delivery of Beclin 1 siRNA and FTY720 to hepatocellular carcinoma by calcium phosphate nanoparticles for enhanced anticancer efficacy.Co-delivery of Aurora-A inhibitor XY-4 and Bcl-xl siRNA enhances antitumor efficacy for melanoma therapy.Codelivery of doxorubicin and JIP1 siRNA with novel EphA2-targeted PEGylated cationic nanoliposomes to overcome osteosarcoma multidrug resistance.
P2860
Q26823523-2DB64F45-BC69-497E-B038-DCD8150367D1Q33635350-4E5FBCE2-1687-47B3-9A44-AE34B14F7580Q33728156-1EB692B4-F939-4959-8961-2A37477DCA2CQ35227495-69AAB869-8CDA-46D8-9288-FFF7840B6862Q36372357-451D36DB-E2D2-4CDC-A380-AF8CED95D278Q36723775-48CFA45F-858D-4B95-A6C8-D9DDA3F3620AQ37469872-410FFC7B-369E-463C-8AD1-90723E3E8227Q37520428-96151F26-6AE1-4E01-9D2C-45C9878C8D22Q37693388-A9923CF6-08F7-41AF-8C97-D56A148CE988Q38555082-8D6F147C-BA4A-49C8-A472-385B3A91D770Q38818984-1E6F5597-AB1C-42E6-B212-BD326E540BF2Q38824421-141ADF87-86C4-4112-8FA7-365FB9E434C2Q38826126-156182B0-C5D7-4A11-8D40-2D338F827589Q39171223-18E73937-BA0D-40A2-AD6A-BCEC3FC42B8AQ39306702-042FBE4E-9073-486A-B593-1F04D0D62800Q39317565-B0DCF46D-93FA-4A06-81CE-AC57CD8E864FQ41893433-99158560-6B25-4F68-A3C5-A234350800DEQ47375034-1EA1847F-4C1F-4BE7-B4D9-448F49BF8938Q49714833-BD4F6F95-C1C2-4EB7-9102-CB7A16AB5090Q52649904-7A23C3D6-15C5-44E2-9AFF-2CF8BBF10282Q54120110-D1755833-9D11-487A-BA99-69119B38F0C8Q55710454-778C52FA-AD64-4A41-8371-BC1E02AFA1F8
P2860
Co-delivery of doxorubicin and Bmi1 siRNA by folate receptor targeted liposomes exhibits enhanced anti-tumor effects in vitro and in vivo.
description
2014 nî lūn-bûn
@nan
2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Co-delivery of doxorubicin and ...... effects in vitro and in vivo.
@ast
Co-delivery of doxorubicin and ...... effects in vitro and in vivo.
@en
Co-delivery of doxorubicin and ...... effects in vitro and in vivo.
@nl
type
label
Co-delivery of doxorubicin and ...... effects in vitro and in vivo.
@ast
Co-delivery of doxorubicin and ...... effects in vitro and in vivo.
@en
Co-delivery of doxorubicin and ...... effects in vitro and in vivo.
@nl
prefLabel
Co-delivery of doxorubicin and ...... effects in vitro and in vivo.
@ast
Co-delivery of doxorubicin and ...... effects in vitro and in vivo.
@en
Co-delivery of doxorubicin and ...... effects in vitro and in vivo.
@nl
P2093
P2860
P356
P1433
P1476
Co-delivery of doxorubicin and ...... effects in vitro and in vivo.
@en
P2093
Chuanrui Xu
Guang Yang
Guangya Xiang
Peng Zhang
Wendian Zhang
P2860
P304
P356
10.7150/THNO.9423
P577
2014-08-24T00:00:00Z